Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma
Mast cells are a significant source of tumor necrosis factor (TNF) superfamily members, such as TNF-alpha, CD30 ligand/CD153 (CD30L) and CD40L/CD154. Furthermore, the expression of some of these proteins in mast cells has been associated with tumorigenesis, and mast cells have been found to be incre...
Gespeichert in:
| Veröffentlicht in: | CANCER IMMUNOLOGY, IMMUNOTHERAPY IMMUNOTHERAPY, 2007-09, Vol.56 (9), p.1407-1415 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1415 |
|---|---|
| container_issue | 9 |
| container_start_page | 1407 |
| container_title | CANCER IMMUNOLOGY, IMMUNOTHERAPY |
| container_volume | 56 |
| creator | Diaconu, Nicolae-Costin Kaminska, Renata Naukkarinen, Anita Harvima, Rauno J Nilsson, Gunnar Harvima, Ilkka T |
| description | Mast cells are a significant source of tumor necrosis factor (TNF) superfamily members, such as TNF-alpha, CD30 ligand/CD153 (CD30L) and CD40L/CD154. Furthermore, the expression of some of these proteins in mast cells has been associated with tumorigenesis, and mast cells have been found to be increased in number in the basal cell carcinoma (BCC) lesion. In this study, we have examined the expression of TNF-alpha, CD30L and CD40L immunoreactivity in mast cells in the healthy-looking skin and lesional skin of ten patients with superficial spreading BCC. Also, the counterparts of these molecules, TNF receptor (TNFR) I and II as well as CD30 and CD40, were analysed immunohistochemically. We found that numbers of mast cells and Kit-positive cells were significantly increased in the dermal BCC lesion. The percentage of CD30L-positive mast cells and the number of CD30-positive cells were significantly increased in the upper dermis of the BCC lesion as well. In addition, the numbers of TNF-alpha-positive mast cells and cells with TNFRI and TNFRII were markedly increased in the upper lesional dermis. In contrast, no mast cells positive for CD40L could be detected, even though the lesional dermis contained increased numbers of CD40 positive cells. The BCC epithelium was positive for TNFRI, TNFRII and CD40, but not for CD30, though the larger basal buds appeared to be less intensely stained for TNFRI and CD40. In conclusion, mast cells positive for CD30L and TNF-alpha, but not CD40L, are increased in number in the lesional dermis in BCC. These data suggest plausible pathways whereby mast cells can be activated and to interact with other cells and thereby contribute to the tumorigenesis in BCC. |
| doi_str_mv | 10.1007/s00262-007-0290-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_571831</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2664204643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-45e4b7e41ba113d6c7b874ffece0bfb19636582dfcca5d4d9d0836e0765d68073</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhi0EokvhB3BBlpC4VKHj7-SEqt2WVqrgUpA4WY4z2aYkztbe8PHvcdhVaStx8uvxM6OZ8UvIawbvGYA5TgBc8yLLAngFhXlCFkyKHCkVe0oWIGQOAsgD8iKlmyw4VNVzcsAM16Wp-IJ8uwg-oktIu0CXKwG079YuNMfLFVOCZkWvPp0Vrt9cO4q_NhFT6sKaDi5tqce-T3Ni7ZLr_16pd9F3YRzcS_KsdX3CV_vzkHw5O71anheXnz9eLE8uCy-V2RZSoawNSlY7xkSjvalLI9sWPULd1qzSQquSN633TjWyqRoohUYwWjW6BCMOSbGrm37iZqrtJnaDi7_t6Dq7D33PCq0yrBQs80f_5Vfd1xM7xrWdJsuVAp3pDzs6owM2HsM2uv5B0sOX0F3b9fjDMgYCVDn3925fIY63E6atHbo0r8oFHKdkDWgteMUz-PYReDNOMeTdWa51_jqppcgU21E-jilFbO96YWBnV9idK-wsZ1fYuYU394f4l7G3gfgD6-yyGg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2664204643</pqid></control><display><type>article</type><title>Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma</title><source>MEDLINE</source><source>SWEPUB Freely available online</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Diaconu, Nicolae-Costin ; Kaminska, Renata ; Naukkarinen, Anita ; Harvima, Rauno J ; Nilsson, Gunnar ; Harvima, Ilkka T</creator><creatorcontrib>Diaconu, Nicolae-Costin ; Kaminska, Renata ; Naukkarinen, Anita ; Harvima, Rauno J ; Nilsson, Gunnar ; Harvima, Ilkka T</creatorcontrib><description>Mast cells are a significant source of tumor necrosis factor (TNF) superfamily members, such as TNF-alpha, CD30 ligand/CD153 (CD30L) and CD40L/CD154. Furthermore, the expression of some of these proteins in mast cells has been associated with tumorigenesis, and mast cells have been found to be increased in number in the basal cell carcinoma (BCC) lesion. In this study, we have examined the expression of TNF-alpha, CD30L and CD40L immunoreactivity in mast cells in the healthy-looking skin and lesional skin of ten patients with superficial spreading BCC. Also, the counterparts of these molecules, TNF receptor (TNFR) I and II as well as CD30 and CD40, were analysed immunohistochemically. We found that numbers of mast cells and Kit-positive cells were significantly increased in the dermal BCC lesion. The percentage of CD30L-positive mast cells and the number of CD30-positive cells were significantly increased in the upper dermis of the BCC lesion as well. In addition, the numbers of TNF-alpha-positive mast cells and cells with TNFRI and TNFRII were markedly increased in the upper lesional dermis. In contrast, no mast cells positive for CD40L could be detected, even though the lesional dermis contained increased numbers of CD40 positive cells. The BCC epithelium was positive for TNFRI, TNFRII and CD40, but not for CD30, though the larger basal buds appeared to be less intensely stained for TNFRI and CD40. In conclusion, mast cells positive for CD30L and TNF-alpha, but not CD40L, are increased in number in the lesional dermis in BCC. These data suggest plausible pathways whereby mast cells can be activated and to interact with other cells and thereby contribute to the tumorigenesis in BCC.</description><identifier>ISSN: 0340-7004</identifier><identifier>ISSN: 1432-0851</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-007-0290-7</identifier><identifier>PMID: 17268792</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Aged ; Aged, 80 and over ; Basal cell carcinoma ; Carcinoma, Basal Cell - immunology ; CD30 antigen ; CD30 Ligand - metabolism ; CD40 antigen ; CD40L protein ; Cell Proliferation ; Dermis ; Epithelium ; Female ; Humans ; Immunohistochemistry ; Immunoreactivity ; Ki-1 Antigen - metabolism ; Lesions ; Ligands ; Male ; Mast cells ; Mast Cells - cytology ; Mast Cells - immunology ; MEDICIN ; MEDICINE ; Middle Aged ; Original ; Skin cancer ; Skin diseases ; Skin Neoplasms - immunology ; Tumor necrosis factor receptors ; Tumor Necrosis Factor-alpha - metabolism ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α ; Tumorigenesis</subject><ispartof>CANCER IMMUNOLOGY, IMMUNOTHERAPY, 2007-09, Vol.56 (9), p.1407-1415</ispartof><rights>Springer-Verlag 2007.</rights><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-45e4b7e41ba113d6c7b874ffece0bfb19636582dfcca5d4d9d0836e0765d68073</citedby><cites>FETCH-LOGICAL-c457t-45e4b7e41ba113d6c7b874ffece0bfb19636582dfcca5d4d9d0836e0765d68073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030587/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030587/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,552,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17268792$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-25506$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:115670845$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Diaconu, Nicolae-Costin</creatorcontrib><creatorcontrib>Kaminska, Renata</creatorcontrib><creatorcontrib>Naukkarinen, Anita</creatorcontrib><creatorcontrib>Harvima, Rauno J</creatorcontrib><creatorcontrib>Nilsson, Gunnar</creatorcontrib><creatorcontrib>Harvima, Ilkka T</creatorcontrib><title>Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma</title><title>CANCER IMMUNOLOGY, IMMUNOTHERAPY</title><addtitle>Cancer Immunol Immunother</addtitle><description>Mast cells are a significant source of tumor necrosis factor (TNF) superfamily members, such as TNF-alpha, CD30 ligand/CD153 (CD30L) and CD40L/CD154. Furthermore, the expression of some of these proteins in mast cells has been associated with tumorigenesis, and mast cells have been found to be increased in number in the basal cell carcinoma (BCC) lesion. In this study, we have examined the expression of TNF-alpha, CD30L and CD40L immunoreactivity in mast cells in the healthy-looking skin and lesional skin of ten patients with superficial spreading BCC. Also, the counterparts of these molecules, TNF receptor (TNFR) I and II as well as CD30 and CD40, were analysed immunohistochemically. We found that numbers of mast cells and Kit-positive cells were significantly increased in the dermal BCC lesion. The percentage of CD30L-positive mast cells and the number of CD30-positive cells were significantly increased in the upper dermis of the BCC lesion as well. In addition, the numbers of TNF-alpha-positive mast cells and cells with TNFRI and TNFRII were markedly increased in the upper lesional dermis. In contrast, no mast cells positive for CD40L could be detected, even though the lesional dermis contained increased numbers of CD40 positive cells. The BCC epithelium was positive for TNFRI, TNFRII and CD40, but not for CD30, though the larger basal buds appeared to be less intensely stained for TNFRI and CD40. In conclusion, mast cells positive for CD30L and TNF-alpha, but not CD40L, are increased in number in the lesional dermis in BCC. These data suggest plausible pathways whereby mast cells can be activated and to interact with other cells and thereby contribute to the tumorigenesis in BCC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Basal cell carcinoma</subject><subject>Carcinoma, Basal Cell - immunology</subject><subject>CD30 antigen</subject><subject>CD30 Ligand - metabolism</subject><subject>CD40 antigen</subject><subject>CD40L protein</subject><subject>Cell Proliferation</subject><subject>Dermis</subject><subject>Epithelium</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Immunoreactivity</subject><subject>Ki-1 Antigen - metabolism</subject><subject>Lesions</subject><subject>Ligands</subject><subject>Male</subject><subject>Mast cells</subject><subject>Mast Cells - cytology</subject><subject>Mast Cells - immunology</subject><subject>MEDICIN</subject><subject>MEDICINE</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Skin cancer</subject><subject>Skin diseases</subject><subject>Skin Neoplasms - immunology</subject><subject>Tumor necrosis factor receptors</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><subject>Tumorigenesis</subject><issn>0340-7004</issn><issn>1432-0851</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><recordid>eNp1kk1v1DAQhi0EokvhB3BBlpC4VKHj7-SEqt2WVqrgUpA4WY4z2aYkztbe8PHvcdhVaStx8uvxM6OZ8UvIawbvGYA5TgBc8yLLAngFhXlCFkyKHCkVe0oWIGQOAsgD8iKlmyw4VNVzcsAM16Wp-IJ8uwg-oktIu0CXKwG079YuNMfLFVOCZkWvPp0Vrt9cO4q_NhFT6sKaDi5tqce-T3Ni7ZLr_16pd9F3YRzcS_KsdX3CV_vzkHw5O71anheXnz9eLE8uCy-V2RZSoawNSlY7xkSjvalLI9sWPULd1qzSQquSN633TjWyqRoohUYwWjW6BCMOSbGrm37iZqrtJnaDi7_t6Dq7D33PCq0yrBQs80f_5Vfd1xM7xrWdJsuVAp3pDzs6owM2HsM2uv5B0sOX0F3b9fjDMgYCVDn3925fIY63E6atHbo0r8oFHKdkDWgteMUz-PYReDNOMeTdWa51_jqppcgU21E-jilFbO96YWBnV9idK-wsZ1fYuYU394f4l7G3gfgD6-yyGg</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>Diaconu, Nicolae-Costin</creator><creator>Kaminska, Renata</creator><creator>Naukkarinen, Anita</creator><creator>Harvima, Rauno J</creator><creator>Nilsson, Gunnar</creator><creator>Harvima, Ilkka T</creator><general>Springer Nature B.V</general><general>Springer-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF2</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20070901</creationdate><title>Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma</title><author>Diaconu, Nicolae-Costin ; Kaminska, Renata ; Naukkarinen, Anita ; Harvima, Rauno J ; Nilsson, Gunnar ; Harvima, Ilkka T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-45e4b7e41ba113d6c7b874ffece0bfb19636582dfcca5d4d9d0836e0765d68073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Basal cell carcinoma</topic><topic>Carcinoma, Basal Cell - immunology</topic><topic>CD30 antigen</topic><topic>CD30 Ligand - metabolism</topic><topic>CD40 antigen</topic><topic>CD40L protein</topic><topic>Cell Proliferation</topic><topic>Dermis</topic><topic>Epithelium</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Immunoreactivity</topic><topic>Ki-1 Antigen - metabolism</topic><topic>Lesions</topic><topic>Ligands</topic><topic>Male</topic><topic>Mast cells</topic><topic>Mast Cells - cytology</topic><topic>Mast Cells - immunology</topic><topic>MEDICIN</topic><topic>MEDICINE</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Skin cancer</topic><topic>Skin diseases</topic><topic>Skin Neoplasms - immunology</topic><topic>Tumor necrosis factor receptors</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diaconu, Nicolae-Costin</creatorcontrib><creatorcontrib>Kaminska, Renata</creatorcontrib><creatorcontrib>Naukkarinen, Anita</creatorcontrib><creatorcontrib>Harvima, Rauno J</creatorcontrib><creatorcontrib>Nilsson, Gunnar</creatorcontrib><creatorcontrib>Harvima, Ilkka T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Uppsala universitet</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>CANCER IMMUNOLOGY, IMMUNOTHERAPY</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diaconu, Nicolae-Costin</au><au>Kaminska, Renata</au><au>Naukkarinen, Anita</au><au>Harvima, Rauno J</au><au>Nilsson, Gunnar</au><au>Harvima, Ilkka T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma</atitle><jtitle>CANCER IMMUNOLOGY, IMMUNOTHERAPY</jtitle><addtitle>Cancer Immunol Immunother</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>56</volume><issue>9</issue><spage>1407</spage><epage>1415</epage><pages>1407-1415</pages><issn>0340-7004</issn><issn>1432-0851</issn><eissn>1432-0851</eissn><abstract>Mast cells are a significant source of tumor necrosis factor (TNF) superfamily members, such as TNF-alpha, CD30 ligand/CD153 (CD30L) and CD40L/CD154. Furthermore, the expression of some of these proteins in mast cells has been associated with tumorigenesis, and mast cells have been found to be increased in number in the basal cell carcinoma (BCC) lesion. In this study, we have examined the expression of TNF-alpha, CD30L and CD40L immunoreactivity in mast cells in the healthy-looking skin and lesional skin of ten patients with superficial spreading BCC. Also, the counterparts of these molecules, TNF receptor (TNFR) I and II as well as CD30 and CD40, were analysed immunohistochemically. We found that numbers of mast cells and Kit-positive cells were significantly increased in the dermal BCC lesion. The percentage of CD30L-positive mast cells and the number of CD30-positive cells were significantly increased in the upper dermis of the BCC lesion as well. In addition, the numbers of TNF-alpha-positive mast cells and cells with TNFRI and TNFRII were markedly increased in the upper lesional dermis. In contrast, no mast cells positive for CD40L could be detected, even though the lesional dermis contained increased numbers of CD40 positive cells. The BCC epithelium was positive for TNFRI, TNFRII and CD40, but not for CD30, though the larger basal buds appeared to be less intensely stained for TNFRI and CD40. In conclusion, mast cells positive for CD30L and TNF-alpha, but not CD40L, are increased in number in the lesional dermis in BCC. These data suggest plausible pathways whereby mast cells can be activated and to interact with other cells and thereby contribute to the tumorigenesis in BCC.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>17268792</pmid><doi>10.1007/s00262-007-0290-7</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | CANCER IMMUNOLOGY, IMMUNOTHERAPY, 2007-09, Vol.56 (9), p.1407-1415 |
| issn | 0340-7004 1432-0851 1432-0851 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_571831 |
| source | MEDLINE; SWEPUB Freely available online; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Basal cell carcinoma Carcinoma, Basal Cell - immunology CD30 antigen CD30 Ligand - metabolism CD40 antigen CD40L protein Cell Proliferation Dermis Epithelium Female Humans Immunohistochemistry Immunoreactivity Ki-1 Antigen - metabolism Lesions Ligands Male Mast cells Mast Cells - cytology Mast Cells - immunology MEDICIN MEDICINE Middle Aged Original Skin cancer Skin diseases Skin Neoplasms - immunology Tumor necrosis factor receptors Tumor Necrosis Factor-alpha - metabolism Tumor necrosis factor-TNF Tumor necrosis factor-α Tumorigenesis |
| title | Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T22%3A31%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increase%20in%20CD30%20ligand/CD153%20and%20TNF-alpha%20expressing%20mast%20cells%20in%20basal%20cell%20carcinoma&rft.jtitle=CANCER%20IMMUNOLOGY,%20IMMUNOTHERAPY&rft.au=Diaconu,%20Nicolae-Costin&rft.date=2007-09-01&rft.volume=56&rft.issue=9&rft.spage=1407&rft.epage=1415&rft.pages=1407-1415&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-007-0290-7&rft_dat=%3Cproquest_swepu%3E2664204643%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2664204643&rft_id=info:pmid/17268792&rfr_iscdi=true |